Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model.
A rat central venous catheter (CVC) infection model was used to assess the activity of LY333328 against vancomycin-resistant Enterococcus faecium (VRE). Via the CVC, animals were challenged with 10(6) cfu of Enterococcus faecium with the VanA phenotype. Eight rats received a single dose of LY333328 and eight rats received saline. Seventy-five per cent of control animals had peripheral bacteraemia and 87.5% had VRE recovered from explanted CVCs at the time they were killed, as compared with 0 and 12.5%, respectively, of the LY333328-treated animals (P < 0.01). All animals in the control group had evidence of metastatic disease compared with none of the treated group (P < 0.01). LY333328 was effective against the strain of VRE tested in this model.
Rupp
M E
ME
Department of Internal Medicine, 984031 University of Nebraska Medical Center, Omaha, NE 68198-4031, USA. merupp@unmc.edu
Fey
P D
PD
Longo
G M
GM
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002408:Catheters, Indwelling / Q000382:microbiology; D004195:Disease Models, Animal; D016984:Enterococcus faecium / Q000187:drug effects; D006020:Glycopeptides; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D000077427:Lipoglycopeptides; D008297:Male; D016459:Prosthesis-Related Infections / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020713:Vancomycin Resistance; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin